Cohesity Strengthens Resilience of Large, Mission-Critical MongoDB Workloads
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Cohesity, the leader in AI-powered data security, today announced a deeper integration with MongoDB, the leading database for modern applications. The new integration provides advanced performance and control capabilities for backup and recovery of MongoDB databases. Cohesity is among the first data protection software providers to deliver MongoDB workload protection through the MongoDB Third Party Backup Ops Manager API. Designed with large, critical datasets in mind, the integration supports the strict resilience requirements of global banking, financial services, and Fortune 500 enterprises. The integration is currently available for Cohesity DataProtect.
.@Cohesity, the leader in AI-powered data security, today announced a deeper integration with MongoDB, the leading database for modern applications, to provide advanced performance and control capabilities for backup and recovery of MongoDB databases.
Share
"With ransomware attacks now commonplace, cyber resilience is a strategic priority for all organizations. This is particularly true of large enterprises, which have a very low tolerance for risk,' said Vasu Murthy, senior vice president and chief product officer, Cohesity. 'Downtime for any reason can mean millions of dollars and massive reputational damage. As trusted providers for many of the world's largest companies, Cohesity and MongoDB are working together to strengthen our customers' ability to bounce back fast.'
Cohesity research finds organizations overestimate their cyber resilience capabilities and maturity—often overlooking deficiencies in data recovery speed and capabilities. In fact, only 2% of respondents in a global survey said they could recover data and restore business processes within 24 hours if a cyberattack occurred. The performance and control capabilities enabled through Cohesity's deepened integration with MongoDB supports customers in meeting stringent recovery point and recovery time objectives.
Advanced capabilities include:
Greater speed – parallel data streams enable billions of objects to be processed instantaneously. At the same time, Cohesity's intelligent backups can get customers' MongoDB databases back online 4X faster than traditional methods.
Robust scalability – a scale-out architecture provides petabyte-sized support on a single platform. Customers can reduce their data footprint with global, variable-length deduplication and compression.
Enhanced security – immutable write once, read many (WORM) storage, data encryption in flight and at rest, continuous data protection, secure SSL authentication, and a multi-layer defense posture based on Zero Trust security principles offer additional security enhancements.
'As the leading document database for modern applications, MongoDB empowers organizations to build, scale, and innovate faster,' said Benjamin Cefalo, senior vice president of product management, MongoDB. 'Our collaboration with Cohesity reinforces that mission by helping customers protect their data with robust, enterprise-grade resilience—without compromising the agility and performance developers expect from our platform.'
'Cohesity continues to broaden and enhance its support for enterprise workloads, including those with critical customer datasets at petabyte scale,' said Juan Orlandini, chief technology officer for North America, Insight. 'The deepened integration with MongoDB addresses the most pressing data security concerns for large enterprises and financial organizations by delivering the speed, scalability, and security they require.'
To learn more about the DataProtect and MongoDB integration, read the Cohesity blog.
Cohesity is the leader in AI-powered data security. Over 13,600 enterprise customers, including over 85 of the Fortune 100 and nearly 70% of the Global 500, rely on Cohesity to strengthen their resilience while providing Gen AI insights into their vast amounts of data. Formed from the combination of Cohesity with Veritas' enterprise data protection business, the company's solutions secure and protect data on-premises, in the cloud, and at the edge. Backed by NVIDIA, IBM, HPE, Cisco, AWS, Google Cloud, and others, Cohesity is headquartered in Santa Clara, CA, with offices around the globe. To learn more, follow Cohesity on LinkedIn, X, and Facebook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Veradigm to Release Business Update June 23 rd and Host Investor Call June 24 th
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Conference ID #13754301. A replay of the call will be available for a period of one year on the Veradigm investor relations website. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Business Wire
2 hours ago
- Business Wire
Satellos Bioscience Shareholders Elect Two New Board Members
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. 'I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,' said Frank Gleeson, Satellos co-founder and CEO. 'We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.' A highly accomplished biotech and pharmaceutical executive, Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB's worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies, including Cimzia, Briviact, Evenity, Rystiggo, Zilbrysq, and Bimzelx. Her leadership was instrumental in advancing both common and rare disease treatments, with a deep and sustained commitment to improving outcomes for underserved patient populations. Prior to UCB, Loew-Friedrich held senior R&D roles at Schwarz Pharma, BASF Pharma, and Hoechst/Aventis, where she contributed to the development and success of market-leading drugs such as Humira, Arava, Actonel, Vimpat, and Neupro. Dr. Ho is a seasoned pharmaceutical and biotech executive with broad leadership experience across commercial strategy, business development, financing, and board governance. He has held senior roles at global companies including Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, with expertise spanning ophthalmology, immunology, oncology, and dermatology. As CEO of Medigene AG, he led a strategic transformation and established and extended key partnerships with BioNTech, Regeneron, WuXi Biologics and EpimAb Biotherapeutics. Previously, as EVP & chief business officer at Connect Biopharma, he was instrumental in raising over $350 million through IPO and private funding. He also serves on the boards of Antennova Inc. and Peptomyc S.L., and as executive-in-residence at New Rhein Healthcare Investors. As part of the Annual General Meeting, Rima Al-awar, Ph.D., William Jarosz, J.D., and William McVicar, Ph.D., did not stand for reelection. 'I want to personally thank Rima, Bill and Bill for their dedicated service, thoughtful leadership and support,' said Gleeson. 'Their guidance helped position Satellos for continued progress, and we wish them all the best in their future endeavors.' About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. 530509798v.1
Business Wire
2 hours ago
- Business Wire
SouthBank Legal Expands Corporate Compliance, White Collar, and Investigations Team With Hire of Former Senior ADM and Caterpillar In-House Counsel Brendan J. Gardiner
SOUTH BEND, Ind.--(BUSINESS WIRE)--SouthBank Legal is pleased to announce that Brendan J. Gardiner has joined the firm as a Partner. Based in Boston, MA, Gardiner will focus his practice on helping companies and institutions manage their compliance and regulatory exposure, including enhancing their compliance programs, conducting due diligence, leading sensitive internal investigations, and designing and implementing effective remediation plans. Gardiner joins the firm's high-profile White Collar and Investigations practice team after almost 20 years as in-house counsel for Archer Daniels Midland (ADM) and Caterpillar Inc. His move highlights an industry trend of prominent in-house lawyers returning to private practice at premier law firms. 'We are excited to have Brendan join us and bring his vast in-house experience to assist CLOs and GCs assess and navigate risk for their companies,' stated Jesse Barrett, SouthBank Legal's Washington, DC managing partner and Chambers USA -ranked White-Collar and Investigations attorney. 'Increasingly, our clients are providing us the opportunity to help them proactively manage a full array of legal, compliance, and geopolitical risks, and Brendan's experience strengthens our ability to partner with clients to understand and address those risks before they materialize. I look forward to working alongside him in advising Fortune 500 and mid-market domestic and international clients in all aspects of their compliance operations.' Before joining SouthBank Legal, Gardiner was Vice President and Deputy General Counsel for ADM, where he oversaw a global team of over 100 attorneys and legal professionals throughout 19 countries, providing a full scope of legal practices and processes to support ADM's operations across 200+ countries. Prior to that, he was Chief Litigation and Regulatory Counsel for ADM. Before joining ADM, he was Lead Counsel, International Trade and Anti-Corruption for Caterpillar Inc., where he advised the company on anti-bribery, international sanctions, and tariff-related matters. Additionally, Gardiner was Lead Regional Counsel (EMEA), based in Brussels, and Lead Business Unit Counsel (Power Generation), based in California, for Caterpillar-owned Solar Turbines, Inc. Complementing his legal background, Gardiner has considerable experience designing and implementing insurance-based solutions to manage legal, operational, and geopolitical risks, having served as Director of Insurance and Risk Management at ADM. 'I am thrilled to be joining such an impressive team of lawyers at SouthBank Legal,' stated Gardiner. 'As the range and complexity of risks that CLOs and GCs are being asked to manage grows, in-house teams are increasingly looking to skilled outside lawyers who can provide high-quality, practical, business-oriented advice in a cost structure that meets their needs. SouthBank is a recognized leader in this space, and I look forward to working with the firm's impressive and growing list of clients across all industries. I have been in their shoes and can help them think about risk holistically and design solutions to address challenges before they arise. Having Jesse, who's a former federal prosecutor, and other incredible attorneys on the same team allows us to handle any range of scenarios, including when engagement with government regulators becomes necessary.' Gardiner clerked for the Honorable Susan H. Black at the U.S. Court of Appeals for the Eleventh Circuit. He received his J.D., magna cum laude, from Notre Dame Law School, where he was the Law Review Executive Editor, and his B.A. from the University of Notre Dame. Gardiner is the latest addition to SouthBank Legal's growing team. Most recently, the firm announced the addition of Maggie King and Gregory Guest. King, a recognized leader in the evolving legal and regulatory frameworks surrounding AI and data, focuses on technology, AI, and intellectual property aspects of business and corporate matters, including licensing and M&A projects. She also counsels clients on governance, risk management, and regulatory compliance related to generative AI, cryptocurrency, and sensitive data. An experienced data scientist, King practiced in a Tier 1 Technology Law group at a top ranked Am Law 100 firm and served as a clerk for Judge Thomas L. Kirsch II on the U.S. Court of Appeals for the Seventh Circuit. Guest has extensive experience with buyers and sellers in both financial and strategic acquisitions, and serves as advisor to entrepreneurs, investors, and closely held businesses. In addition, he advises on corporate workouts and restructuring. Guest clerked for the Honorable Lee M. Jackwig on the U.S. Bankruptcy Court for the Southern District of Iowa and practiced at an Am Law 200 firm in Michigan. SouthBank Legal, a Chambers USA ranked firm, routinely delivers smart, cost-effective business solutions to Fortune 500 global leaders as well as early-stage industry disrupters, guiding and fighting for clients in their highest-profile, highest-risk litigation from its offices in Washington, DC, Grand Rapids, MI, and northern Indiana. For more information, please visit
